Atonco Pharma
  • Home
  • Team
  • Technology
  • Pipeline
  • Partners
  • Contact
  • News
  • Français
Select Page

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Search

Recent Posts

  • ATO-101™: A THERAPEUTIC ADVANCE FOR THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
  • ATONCO AND GIP ARRONAX SIGN CONTRACT TO DEVELOP AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY
  • ATONCO AND UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION ON PHASE 1-2a CLINICAL STUDY OF ATO-101™
  • ATONCO AND MINERVA IMAGING JOIN FORCES IN TARGETING BLADDER CANCER
  • TARGETED ALPHA THERAPY CANDIDATE : BLADDER CANCER STUDY COMPLETES ENROLMENT

News

  • March 2025
  • April 2024
  • March 2024
  • October 2023
  • August 2022
  • March 2022
  • December 2021
  • May 2021
  • April 2021
  • March 2020
  • December 2019

Informations

  • Home
  • Team
  • Technology
  • Pipeline
  • Partners
  • Contact
  • News
  • Français

Legal

  • Legal

Contact us

Atonco Pharma
Pôle Bio-Ouest, rue du Moulin de la Rousselière 44800 Saint Herblain
France
info@atonco-pharma.com